Kimberly Warren to Double-Blind Method
This is a "connection" page, showing publications Kimberly Warren has written about Double-Blind Method.
Connection Strength
0.337
-
Warren KR, Wehring HJ, Liu F, McMahon RP, Chen S, Chester C, Kelly DL. Effects of intranasal oxytocin on satiety signaling in people with schizophrenia. Physiol Behav. 2018 05 15; 189:86-91.
Score: 0.149
-
Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol. 2013 Feb; 33(1):118-20.
Score: 0.105
-
Elkashef A, Bra?ic JR, Cantelina LR, Kahn R, Chiang N, Ye W, Zhou Y, Mojsiak J, Warren KR, Crabb A, Hilton J, Wong DF, Vocci F. A cholecystokinin B receptor antagonist and cocaine interaction, phase I study. CNS Neurosci Ther. 2019 01; 25(1):136-146.
Score: 0.038
-
Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses. 2011 Apr; 5(1):17-25.
Score: 0.023
-
Kelly DL, Gorelick DA, Conley RR, Boggs DL, Linthicum J, Liu F, Feldman S, Ball MP, Wehring HJ, McMahon RP, Huestis MA, Heishman SJ, Warren KR, Buchanan RW. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol. 2011 Feb; 31(1):86-91.
Score: 0.023